Robert Hofmeister, PhD

Dr. Hofmeister joined Myeloid in February 2024. Previously, he was the CSO at Resonance Medicine where he drove the development of their research and development strategy, leveraging their therapeutic modality. Previously, he served as CSO at TCR 2 Therapeutics where he started as employee number one and was instrumental in building and leading the R&D function, driving the development of their proprietary TRuC ® -T cell platform from concept to first cleared IND (TC-210 program) and successfully contributed to taking the company public as well as securing multi-million dollar rounds of fundraising. Dr. Hofmeister also held various roles at EMD Serono where he was involved in the development of now approved Bavencio (avelumab) and building the company’s immuno-oncology platform. He started his biotech career at Micromet AG, now Amgen Research Munich, where he helped shape the development of Blincyto (blinatumomab), the first FDA-approved bispecific antibody for the treatment of refractory ALL.

Dr. Hofmeister received his Ph.D. from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin-1. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute.